Effective Improvement of Symptoms in Patients with Acute Migraine by GR43175 Administered in Dispersible Tablets

GR43175, a selective 5-HT1-like agonist, was administered as oral
dispersible tablets in an open, uncontrolled dose-ranging study to
assess its efficacy as an agent for acute migraine. Nine patients,
all with well established attacks, were assessed for changes in
severity of headache and associated symptoms over 2 h. Drug
absorption was compared during and between attacks in five
patients. Doses of 140 mg and 280 mg resulted in complete relief of
all symptoms within 2 h. Treatment was well tolerated in all
patients.